Matthew Kurian, Assistant Professor of Medicine at the University of Kentucky College of Medicine and Physician at St. Elizabeth Healthcare, shared a post on LinkedIn:
“PRESS RELEASE – Roche evERA Phase III Trial
Giredestrant + Everolimus Shows Significant PFS Benefit in ER+/HER2- mBC After CDK4/6 Roche announced positive results from the Phase III evERA study:
- Progression-free survival improved vs standard endocrine therapy + everolimus in both the overall and ESR1-mutated groups
- OS trending positive, follow-up ongoing
- No new safety signals
Phase 1–2 safety: mostly mild fatigue, nausea, arthralgia, occasional asymptomatic bradycardia, and manageable neutropenia – similar to other oral SERDs.
For those hesitant to swap CDK4/6, this all-oral SERD + mTOR inhibitor regimen could be a very compelling next-line strategy.”
More posts featuring Matthew Kurian on OncoDaily.